Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

NEEDHAM, MA - Verastem, Inc. (NASDAQ:VSTM), a $247.5 million market cap biopharmaceutical company focused on developing and ...

Verastem Oncology (NASDAQ: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...

Verastem, Inc. (NASDAQ: VSTM) recently disclosed in an 8-K filing with the Securities and Exchange Commission that on January 13, 2025, the company entered into a Note Purchase Agreement with RGCM SA ...

Oncology announced the appointment of Matthew E. Ros as chief operating officer. In his role, Mr. Ros will report to Dan ...

Geode Capital Management LLC increased its position in Verastem, Inc. (NASDAQ:VSTM – Free Report) by 67.6% during the third quarter, according to the company in its most recent 13F filing with the ...

BOSTON, January 15, 2025--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to ...

Verastem, Inc. (NASDAQ:VSTM) recently announced that the FDA has accepted their NDA for accelerated approval for the combination of avutometinib and defactinib “recurrent low-grade serous ...

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ovarian carcinoma. Financially, VSTM has limited cash reserves ...

Verastem Oncology (VSTM) said it has exercised early the option to license from GenFleet Therapeutics VS-7375, a potential ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced preliminary clinical data for ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant ...